A notable development is the launch of Wegovy by Novo Nordisk A/S in March 2024, the first once-weekly GLP-1 therapy designed to manage weight effectively, showcasing a safe and convenient approach for patients
Gastrointestinal Side Effects: Common issues include nausea, vomiting in a few, diarrhea or constipation, particularly when starting treatment or increasing the dose
La revista de Editorial Planeta "AO CERO" se hace eco de las increbles propiedades del HIGO-TINTO
Research potential persists: Despite clinical failure, AOD-9604 remains useful as a laboratory model for studying growth-hormone fragment signaling, adipocyte biochemistry, and peptide-receptor interactions
Authors also thank Elisabeth Bascuana, Jordi Hernndez, Montserrat Jimnez, Damir Garcia-Cehic, Leonardo Nieto-Aponte, and Josep Gregori for their help in specimen processing